KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to $8.1 million.

  • Supernus Pharmaceuticals' Net Cash Flow rose 13972.37% to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.1 million, marking a year-over-year increase of 29135.08%. This contributed to the annual value of -$5.7 million for FY2024, which is 6832.17% up from last year.
  • Supernus Pharmaceuticals' Net Cash Flow amounted to $8.1 million in Q3 2025, which was up 13972.37% from $28.9 million recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Net Cash Flow peaked at $369.1 million during Q1 2023, and registered a low of -$437.5 million during Q2 2023.
  • Moreover, its 5-year median value for Net Cash Flow was -$11.7 million (2024), whereas its average is -$7.1 million.
  • Examining YoY changes over the last 5 years, Supernus Pharmaceuticals' Net Cash Flow showed a top increase of 52075.26% in 2023 and a maximum decrease of 85805.1% in 2023.
  • Supernus Pharmaceuticals' Net Cash Flow (Quarter) stood at -$11.8 million in 2021, then tumbled by 55.08% to -$18.4 million in 2022, then dropped by 8.49% to -$19.9 million in 2023, then skyrocketed by 288.94% to $37.7 million in 2024, then plummeted by 78.46% to $8.1 million in 2025.
  • Its last three reported values are $8.1 million in Q3 2025, $28.9 million for Q2 2025, and $46.5 million during Q1 2025.